Clinical

Dataset Information

0

Outcome of Vitamin D supplementation alongwith the standard treatment in Lymphoma Patients.


ABSTRACT: Primary outcome(s): a)To study the association of baseline vitamin D level with Overall Response Rate(ORR) in patients with newly diagnosed lymphoma. b)To study the effect of vitamin D supplementation on Overall Response Rate (ORR) in the vitamin D deficient patients with newly diagnosed lymphoma. Timepoint: August 2018 to May 2020

DISEASE(S): Follicular Lymphoma Grade Ii,A- Cutaneous T-cell Lymphoma, Unspecified,Mature T/nk-cell Lymphomas, Unspecified,Angioimmunoblastic T-cell Lymphoma,Extranodal Marginal Zone B-cell Lymphoma Of Mucosa-associated Lymphoid Tissue [malt-lymphoma],Cutaneous Follicle Center Lymphoma,Follicular Lymphoma, Unspecified,Mixed Cellularity Hodgkin Lymphoma,Follicular Lymphoma Grade Iiib,Follicular Lymphoma Grade Iiia,Anaplastic Large Cell Lymphoma, Alk-positive,Malignant Immunoproliferative Disease, Unspecified,Malignant Neoplasm Of Lymphoid, Hematopoietic And Related Tissue, Unspecified,Mycosis Fungoides,Hodgkin Lymphoma, Unspecified,Follicular Lymphoma Grade Iii, Unspecified,Hepatosplenic T-cell Lymphoma,Blastic Nk-cell Lymphoma,Diffuse Follicle Center Lymphoma,Nodular Lymphocyte Predominant Hodgkin Lymp,Mediastinal (thymic) Large B-celllymphoma,Follicular Lymphoma Grade I,Lymphocyte Depleted Hodgkin Lymphoma,Burkitt Lymphoma,Diffuse Large B-cell Lymphoma,Enteropathy-type (intestinal) T-cell Lymphoma,Lymphoblastic (diffuse) Lymphoma,Anaplastic Large Cell Lymphoma, Alk-negative,Mantle Cell Lymphoma,Extranodal Nk/t-cell Lymphoma, Nasal Type,Lymphocyte-rich Hodgkin Lymphoma

PROVIDER: 2588839 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2023-08-30 | GSE218048 | GEO
2018-05-01 | GSE98588 | GEO
2008-11-13 | E-GEOD-13314 | biostudies-arrayexpress
2014-04-08 | GSE56583 | GEO
2011-12-16 | GSE34339 | GEO
2014-04-08 | E-GEOD-56583 | biostudies-arrayexpress
2023-02-09 | E-MTAB-12650 | biostudies-arrayexpress
2019-06-20 | GSE84269 | GEO
2019-06-20 | GSE84267 | GEO
2023-08-30 | GSE239308 | GEO